Skip to main content

Development of Innovative Drugs via Modeling with MATLAB

A Practical Guide

  • Book
  • © 2014

Overview

  • Provides concepts for the creation of drug-disease models

  • Written from the industry perspective

  • Based on many years of experience

  • Includes supplementary material: sn.pub/extras

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

Keywords

About this book

The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens?

Written from the industry perspective and based on many years of experience, this book offers:

- Concepts for creation of drug-disease models, introduced and supplemented with extensive MATLAB programs

- Guidance for exploration and modification of these programs to enhance the understanding of key principles

- Usage of differential equations to pharmacokinetic, pharmacodynamic and (patho-) physiologic problems thereby acknowledging their dynamic nature

- A range of topics from single exponential decay to adaptive dosing, from single subject exploration to clinical trial simulation, and from empirical to mechanistic disease modeling.

Students with an undergraduate mathematical background or equivalent education, interest in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development.

Authors and Affiliations

  • Pharma Research and Early Development (p Translational Research Sciences (TRS), F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Ronald Gieschke

  • F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Daniel Serafin

Bibliographic Information

Publish with us